U.S. Markets open in 2 hrs 28 mins

Enanta Pharma's liver disease drug meets mid-stage study goal

Sept 25 (Reuters) - Enanta Pharmaceuticals Inc said on Wednesday its drug to treat non-alcoholic steatohepatitis (NASH) met the main goal of reducing levels of elevated liver enzymes in a mid-stage study.

The company said its experimental drug significantly reduced the levels of alanine aminotransferase (ALT) versus a placebo. (Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)